中国临床药学杂志

目的 建立注射用盐酸乌拉地尔的药物利用评价标准，为临床合理使用注射用盐酸乌拉地尔提供参考。方法 基于注射用盐酸乌拉地尔最新版说明书，结合相关指南、专家共识，采用属性层次模型结合优劣解距离法建立基于加权优劣解距离法的注射用盐酸乌拉地尔药物利用评价标准。采用建立的标准对2024年1月至6月使用注射用盐酸乌拉地尔的病历进行回顾性评价。结果 166份病历的相对接近度（Ci）为48.39%～100.00%，其中Ci≥80%（病历评级为合理）的有8份（占4.82%）;60%≤Ci<80%（病历评级为基本合理）的有132份（占79.52%）;Ci<60%（病历评级为不合理）的有26份（占15.66%）。注射用盐酸乌拉地尔主要不合理问题主要表现在血压监测、用药疗程和药物相互作用方面。结论 建立的注射用盐酸乌拉地尔药物利用评价标准科学、简便，为开展注射用盐酸乌拉地尔的合理性评价提供了新的方法。该院注射用盐酸乌拉地尔的应用存在许多不合理用药问题，需要加强管控。

AIM To establish drug utilization evaluation(DUE) standards of urapidil hydrochloride for injection, providing a reference for the rational use of drugs in clinical practice. METHODS Based on the latest version of the instructions for injection of urapidil hydrochloride, combined with relevant guidelines and expert consensus, the attribute hierarchy model(AHM) combined with the technique for order preference by similarity to an ideal solution(TOPSIS) was used to retrospectively evaluate the medical records of injection of urapidil hydrochloride used from January to June 2024. RESULTS A total of 166 case records were evaluated using the weighted TOPSIS method, with the coefficient of relative proximity(Ci) ranging from 48.39% to 100.00%. Of these, 8 cases(4.82%) were rated as reasonable with Ci ≥ 80%; 132 cases(79.52%) were rated as basically reasonable with 60% ≤ Ci < 80%; and 26 cases(15.66%) were rated as unreasonable with Ci < 60%. The main unreasonable problems of urapidil hydrochloride for injection were blood pressure monitoring, medication course, drug interaction, and so on. CONCLUSION The weighted TOPSIS method-based drug utilization evaluation standard for injection-use urapidil hydrochloride is scientific and simple, providing a new approach to the rational evaluation of the drug. There are significant issues with the inappropriate use of urapidil hydrochloride for injection in the hospital, requiring improved management.